Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
Long non-coding RNAs (lncRNAs) are emerging as regulators in cancer development and progression, and aberrant lncRNA profiles have been reported in several cancers. Here, we evaluated the potential of using the maternally expressed gene 3 (MEG3) tissue level as a prognostic marker in high-grade sero...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/966 |
| _version_ | 1797570721883357184 |
|---|---|
| author | Marianna Buttarelli Marta De Donato Giuseppina Raspaglio Gabriele Babini Alessandra Ciucci Enrica Martinelli Pina Baccaro Tina Pasciuto Anna Fagotti Giovanni Scambia Daniela Gallo |
| author_facet | Marianna Buttarelli Marta De Donato Giuseppina Raspaglio Gabriele Babini Alessandra Ciucci Enrica Martinelli Pina Baccaro Tina Pasciuto Anna Fagotti Giovanni Scambia Daniela Gallo |
| author_sort | Marianna Buttarelli |
| collection | DOAJ |
| description | Long non-coding RNAs (lncRNAs) are emerging as regulators in cancer development and progression, and aberrant lncRNA profiles have been reported in several cancers. Here, we evaluated the potential of using the maternally expressed gene 3 (MEG3) tissue level as a prognostic marker in high-grade serous ovarian cancer (HGSOC), the most common and deadliest gynecologic malignancy. To the aim of the study, we measured MEG3 transcript levels in 90 pre-treatment peritoneal biopsies. We also investigated MEG3 function in ovarian cancer biology. We found that high MEG3 expression was independently associated with better progression-free (<i>p</i> = 0.002) and overall survival (<i>p</i> = 0.01). In vitro and in vivo preclinical studies supported a role for MEG3 as a tumor suppressor in HGSOC, possibly through modulation of the phosphatase and tensin homologue (PTEN) network. Overall, results from this study demonstrated that decreased MEG3 is a hallmark for malignancy and tumor progression in HGSOC. |
| first_indexed | 2024-03-10T20:29:22Z |
| format | Article |
| id | doaj.art-c89affec4cbc4f4c8b3b880968ad4786 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T20:29:22Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c89affec4cbc4f4c8b3b880968ad47862023-11-19T21:33:50ZengMDPI AGCancers2072-66942020-04-0112496610.3390/cancers12040966Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian CancerMarianna Buttarelli0Marta De Donato1Giuseppina Raspaglio2Gabriele Babini3Alessandra Ciucci4Enrica Martinelli5Pina Baccaro6Tina Pasciuto7Anna Fagotti8Giovanni Scambia9Daniela Gallo10Unit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, ItalyUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, ItalyUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, ItalyDepartment of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, ItalyUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, ItalyUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, ItalyDepartment of Life Sciences and Public Health, Section of Gynecology and Obstetrics, Università Cattolica del Sacro Cuore, 00168 Rome, ItalyDepartment of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, ItalyDepartment of Life Sciences and Public Health, Section of Gynecology and Obstetrics, Università Cattolica del Sacro Cuore, 00168 Rome, ItalyDepartment of Life Sciences and Public Health, Section of Gynecology and Obstetrics, Università Cattolica del Sacro Cuore, 00168 Rome, ItalyUnit of Translational Medicine for Woman and Child Health, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, ItalyLong non-coding RNAs (lncRNAs) are emerging as regulators in cancer development and progression, and aberrant lncRNA profiles have been reported in several cancers. Here, we evaluated the potential of using the maternally expressed gene 3 (MEG3) tissue level as a prognostic marker in high-grade serous ovarian cancer (HGSOC), the most common and deadliest gynecologic malignancy. To the aim of the study, we measured MEG3 transcript levels in 90 pre-treatment peritoneal biopsies. We also investigated MEG3 function in ovarian cancer biology. We found that high MEG3 expression was independently associated with better progression-free (<i>p</i> = 0.002) and overall survival (<i>p</i> = 0.01). In vitro and in vivo preclinical studies supported a role for MEG3 as a tumor suppressor in HGSOC, possibly through modulation of the phosphatase and tensin homologue (PTEN) network. Overall, results from this study demonstrated that decreased MEG3 is a hallmark for malignancy and tumor progression in HGSOC.https://www.mdpi.com/2072-6694/12/4/966MEG3lncRNAsprogression-free survivaloverall survivalcancer biomarkersovary |
| spellingShingle | Marianna Buttarelli Marta De Donato Giuseppina Raspaglio Gabriele Babini Alessandra Ciucci Enrica Martinelli Pina Baccaro Tina Pasciuto Anna Fagotti Giovanni Scambia Daniela Gallo Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer Cancers MEG3 lncRNAs progression-free survival overall survival cancer biomarkers ovary |
| title | Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer |
| title_full | Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer |
| title_fullStr | Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer |
| title_full_unstemmed | Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer |
| title_short | Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer |
| title_sort | clinical value of lncrna meg3 in high grade serous ovarian cancer |
| topic | MEG3 lncRNAs progression-free survival overall survival cancer biomarkers ovary |
| url | https://www.mdpi.com/2072-6694/12/4/966 |
| work_keys_str_mv | AT mariannabuttarelli clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT martadedonato clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT giuseppinaraspaglio clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT gabrielebabini clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT alessandraciucci clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT enricamartinelli clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT pinabaccaro clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT tinapasciuto clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT annafagotti clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT giovanniscambia clinicalvalueoflncrnameg3inhighgradeserousovariancancer AT danielagallo clinicalvalueoflncrnameg3inhighgradeserousovariancancer |